CO-FOUNDER, ACTING CHIEF EXECUTIVE OFFICER, AND CHIEF MEDICAL OFFICER
Frances L. Johnson, MD is a founding member, Acting Chief Executive Officer, and Chief Medical Officer of Viewpoint Molecular Targeting, Inc. Dr. Johnson is a physician scientist and entrepreneur whose experience includes co-founding a biomedical startup (XDx; now CareDx) while faculty at Stanford University. Dr. Johnson completed her undergraduate and graduate degrees in medicine at the University of Washington followed by residency at the University of California San Francisco and fellowship at Stanford University. Dr. Johnson is a primary inventor of the molecular diagnostic technology she developed at Stanford that is a cornerstone of CareDx (market capitalization of $1B). Dr. Johnson remained in academics during the growth phase of CareDx and has led heart transplant teams at three university academic medical centers before co-founding Viewpoint Molecular Targeting with Dr. Schultz and Mr. Coleman. As CEO/CMO at Viewpoint, Dr. Johnson has successfully secured seven Phase I and Phase II National Institutes of Health/National Cancer Institute funded Small Business Innovation Research Grants and Contract Projects ($6M). Dr. Johnson has successfully developed a team that is now set for two IND approvals in 2020.
CO-FOUNDER AND CHIEF SCIENCE OFFICER
Michael K. Schultz, PhD is a founding member and Chief Science Officer of Viewpoint Molecular Targeting, Inc. Dr. Schultz is concurrently an Associate Professor of Radiology and Free Radical and Radiation Biology at the University of Iowa. Dr. Schultz has held continuous funding for over a decade from the National Institutes of Health (NIH)/ National Cancer Institute (NCI) and has published over 75 peer-reviewed journal articles, book chapters, and invited publications. Dr. Schultz is a Principal Investigator on a currently funded NIH Research Project Grant (R01) to conduct a Phase 1 clinical imaging and therapy trial of VMT-a-NET at the University of Iowa and has served as Co-Investigator (with acting CEO and CMO Frances Johnson, MD of Viewpoint) on over $6M of NCI funded Small Business Innovation Research grant projects. In addition to his role on the current R01 ($3.5M), Dr. Schultz is a Project Leader for the University of Iowa NIH sponsored Specialized Project of Research Excellence in Neuroendocrine Tumors (a $10M, 5-year grant) and has been the primary architect, Principal Investigator, or Co-Investigator on over $20M in total of grants from the NIH, Nuclear Regulatory Commission, Department of Energy, Department of Homeland Security, and industry funded research projects. Dr. Schultz has 5 years of experience in product management in radiation detectors, electronics, and software (PerkinElmer/Ametec); 17 years experience in radiopharmaceutical CMC/IND approvals; and served as a consultant to Algeta ASA (acquired by Bayer) on the CMC for the first alpha-particle targeted therapy approved in the United States (Xofigo).
CO-FOUNDER AND MANAGING DIRECTOR
Heyward H. Coleman, MBA is a founding member and Managing Director of Viewpoint Molecular Targeting, Inc. Mr. Coleman is a serial entrepreneur, who started his career in business with an MBA from Harvard School of Business after completing both service as an Officer in the United States Navy as well as receiving a Masters Degree in Nuclear Physics from Duke University. Mr. Coleman’s previous achievements include founding, building, and eventually selling the largest privately held radioanalytical chemistry company in the United States (Environmental Physics; now General Engineering Laboratories). Mr. Coleman served as the inaugural CEO of Viewpoint and has assumed the role of Managing Director to coordinate activities at General Engineering Laboratories, where the company will be expanding production of the VMT-a-GEN lead-212 radioisotope production device.
CHAIRMAN OF THE ADVISORY BOARD
Curtis Nelson, BBA serves as the current Chairman of the Advisory Board at Viewpoint and is concurrently the President and CEO of the Economic Development Corporation. As a 1974 graduate from the University of Iowa, Mr. Nelson holds a BBA in Marketing and is also the author of The Recipe for Business Success. Mr. Nelson has over thirty-five years of successful national and international business creation and leadership experience – directing the development and successful launch of over 100 new businesses and more than 500 new products for the medical, health, communications, IT, military, transportation, food, and gardening industries worldwide. Mr. Nelson’s areas of expertise include starting-up and financing through a product development life cycle as well as management consulting in financials. Mr. Nelson is a successful entrepreneur, investor, seasoned public speaker and consultant, and three-time veteran of Inc. Magazine’s 500 Fastest-Growing Private Companies® list (#48, #67, #225).
ADVISORY BOARD MEMBER
Michael Graham, MD PhD has been a leader in nuclear medicine and radiopharmaceuticals for over 30 years. Dr. Graham is a Professor of Radiology at the University of Iowa; a former President of the Society of Nuclear Medicine; and a current Co-Chair of the SNMMI Clinical Trials Network, which is an SNMMI entity that has been specifically formed to assist early stage companies in accelerating new radiopharmaceuticals through clinical stages of development. Dr. Graham has been a Principal Investigator on multiple IND filings and has recently provided leadership in securing an NDA for gallium-68 DOTATOC for imaging of neuroendocrine tumors through his efforts at the Clinical Trials Network. Dr. Graham earned a BS in Engineering from Massachusetts Institute of Technology; a PhD from University of California, Berkeley; and an MD from the University of California San Francisco. He served as Head of Nuclear Medicine at the University of Iowa for over a decade and is a world-renown content expert in image-guided radionuclide therapy for cancer and clinical trial design for this application.
ADVISORY BOARD MEMBER
Jeff Clanton, MS PharmD BCNP has been a leader in nuclear pharmacy and nuclear medicine for over 40 years and is a key opinion leader in this field. Dr. Clanton was a long-standing member of the Pharmacy and Therapeutics committee, Human Subjects Radiation Committee, Radiation Safety Committee, and Chairman of Radioactive Drug Research Committee. Dr. Clanton co-founded and co-owned an independent, commercial radiopharmacy and was responsible for operations and regulatory compliance. In addition, as a consultant for PETNET Pharmaceutical Services, he was responsible for the placement, build-out, training, compliance and start-up of three PET cyclotron manufacturing facilities with pharmacies in Kentucky, Arkansas, and Louisiana. In recognition of his leadership, Dr. Clanton is the 2020 recipient of the William H. Briner Distinguished Achievement Award in Nuclear Pharmacy Practice. Dr. Clanton has provided leadership and oversight on numerous CMC/IND submissions as well as radiopharmacy operations and regulatory guidance for compliance (NRC, USP, cGMP and pharmacy law). During his 38+ year career at Vanderbilt University Medical Center, Dr. Clanton was Director of Radiopharmacy Services; Manager of the Cyclotron Facility; and a member of the Medical School Faculty, where he was responsible for production, operation, and delivery of prepared radiopharmaceuticals to patients. Dr. Clanton has authored or co-authored 90+ peer-reviewed scientific papers and 100+ abstracts for presentation at national meetings.
ADVISORY BOARD MEMBER
Nannette Rich, BS is Vice President of Sales and Marketing at Telix Pharmaceuticals. Ms. Rich has over 15 years of experience in business development, portfolio management, and marketing and sales in the radiopharmaceuticals and nuclear medicine (radioisotope imaging and therapeutics) business for companies including Mallinkrodt Pharmaceuticals, Covidien, and ETHEX Corporation. In her roles with these companies, Ms. Rich has provided leadership and guidance for founders and mature company management on product development, company process development, and regulatory strategy execution. Ms. Rich has consistently held roles in which she brought talent in the direction of marketing and sales for larger pharmaceutical companies as well as strategic clinical trial design– leading companies from conception and formation through product launch and NDA approvals.
ADVISORY BOARD MEMBER
Sue O’Dorisio, MD PhD is a Distinguished Professor of Pediatrics at the University of Iowa and a world renowned leader in the adaptation of receptor-targeted image-guided radionuclide therapies for pediatric applications. Dr. O’Dorisio earned a BS in Mathematics from Creighton University, and MS and PhD in Biochemistry from the University of Nebraska, and an MD cum laude from the Ohio State University, Columbus, OH. Dr. O’Dorisio is co-author of the biomedical literature The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors and The North American Neuroendocrine Tumor Society Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors: Pheochromocytoma, Paraganglioma, and Medullary thyroid cancer. Dr. O’Dorisio has served as Principal Investigator on numerous National Cancer Institute (NCI) supported clinical and preclinical investigations and is the Principal Investigator of the University of Iowa NCI funded ($10M) Specialized Program of Research Excellence in Neuroendocrine Tumors (NET SPORE). This program under Dr. O’Dorisio’s leadership is recognized as the only NET SPORE funded by the NCI in the United States and is also the only non-European based European Neuroendocrine Tumor Society Center of Excellence. Dr. O’Dorisio has been Principal Investigator on numerous investigator-initiated INDs for radionuclide therapy trials for pediatrics and brings a wealth of knowledge and understanding to the introduction of Viewpoint products for pediatric indications of neuroblastoma, medulloblastoma, paraganglioma, and pheochromocytoma.